Charlotta Wallinder

TL;DR: The first druglike selective angiotensin II AT(2) receptor agonist (21) with a K(i) value of 0.4 nM with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44(mapk), and enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats.

TL;DR: First data using C21 revealed tissue protective effects and functional improvement after myocardial infarction and in hypertension-induced end organ damage, notably in a blood-pressure independent way.

TL;DR: Results indicate that AT2R is involved in early adipocyte differentiation, while in mature adipocytes and in a model of insulin resistance AT1R activation restores normal adipocyte morphology and improves insulin sensitivity.

TL;DR: Two series of compounds structurally related to 1 but with a meta substitution pattern have now been synthesized and biologically evaluated for their affinity to the AT(1) and AT(2) receptors, and four of the five compounds acted as potent AT( 2) receptor antagonists.

TL;DR: The possibility that selective AT2R activation by non-peptide and highly selective agonists, acting on neuronal plasticity, could represent new pharmacological tools that may help improve impaired cognitive performance in AD and other neurological cognitive disorders is highlighted.